Fate Therapeutics Inc financial data

Symbol
FATE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
12278 Scripps Summit Drive, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 843 % -3.99%
Return On Equity -49.5 % -29.8%
Return On Assets -36.6 % -28.9%
Operating Margin -1.54K % -414%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115M shares +0.67%
Common Stock, Shares, Outstanding 114M shares +15.5%
Entity Public Float 369M USD -20.1%
Common Stock, Value, Issued 114K USD +15.2%
Weighted Average Number of Shares Outstanding, Basic 114M shares +15.5%
Weighted Average Number of Shares Outstanding, Diluted 114M shares +15.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 13.6M USD -78.5%
Research and Development Expense 135M USD -21.8%
General and Administrative Expense 74.2M USD -8.94%
Operating Income (Loss) -210M USD -10.4%
Net Income (Loss) Attributable to Parent -186M USD -15.7%
Earnings Per Share, Basic -1.64 USD/shares 0%
Earnings Per Share, Diluted -1.64 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.1M USD -13.9%
Accounts Receivable, after Allowance for Credit Loss, Current 3.54M USD +93.8%
Assets, Current 292M USD -12%
Property, Plant and Equipment, Net 64.4M USD -33.5%
Operating Lease, Right-of-Use Asset 46.5M USD -24.6%
Other Assets, Noncurrent 9K USD 0%
Assets 441M USD -12.9%
Accounts Payable, Current 9.37M USD +98.5%
Accrued Liabilities, Current 21.3M USD -22.4%
Contract with Customer, Liability, Current 393K USD -42.6%
Liabilities, Current 38.5M USD -1.46%
Operating Lease, Liability, Noncurrent 77.8M USD -20%
Accumulated Other Comprehensive Income (Loss), Net of Tax 268K USD +1687%
Retained Earnings (Accumulated Deficit) -1.4B USD -15.4%
Stockholders' Equity Attributable to Parent 319M USD -13.5%
Liabilities and Equity 441M USD -12.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.4M USD -15.6%
Net Cash Provided by (Used in) Financing Activities 95.5M USD +46029%
Net Cash Provided by (Used in) Investing Activities 17.3M USD +85.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 114M shares +15.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 79.5M USD
Deferred Tax Assets, Valuation Allowance 362M USD +11.8%
Deferred Tax Assets, Gross 374M USD +9.18%
Operating Lease, Liability 85.3M USD -17.6%
Payments to Acquire Property, Plant, and Equipment 86K USD -97.3%
Lessee, Operating Lease, Liability, to be Paid 134M USD -18%
Property, Plant and Equipment, Gross 99.5M USD -31.1%
Operating Lease, Liability, Current 7.42M USD +20.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.1M USD -26.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 14.4M USD -2.03%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 48.4M USD -18.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.4M USD -26.8%
Deferred Tax Assets, Operating Loss Carryforwards 147M USD +30.3%
Preferred Stock, Shares Issued 2.76M shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 70.5M USD +18.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.3M USD -35.7%
Additional Paid in Capital 1.72B USD +8.63%
Preferred Stock, Shares Outstanding 2.76M shares
Depreciation, Depletion and Amortization 4.82M USD +15%
Share-based Payment Arrangement, Expense 41.5M USD -4.52%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%